XHKG2126
Market cap67mUSD
Dec 27, Last price
1.29HKD
1D
-0.77%
1Q
-18.35%
IPO
-93.86%
Name
JW (Cayman) Therapeutics Co Ltd
Chart & Performance
P/E
—
P/S
2.82
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
1.81%
Rev. gr., 5y
281.55%
Revenues
174m
+19.32%
Net income
-768m
L-9.23%
CFO
-398m
L-25.77%
Earnings
Jun 18, 2025
Profile
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. The company offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers. The company's pipeline products include JWCAR129, an autologous CAR-T therapy for the treatment of multiple myeloma; JWATM204, a TCR T-cell therapy candidate for the treatment of HCC; and JWATM203, an autologous T-cell receptor mimic T-cell therapy targeting alpha-fetoprotein for the treatment of hepatocellular carcinoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 173,856 19.32% | 145,702 373.10% | 30,797 | |||
Cost of revenue | 617,004 | 865,404 | 808,399 | |||
Unusual Expense (Income) | ||||||
NOPBT | (443,148) | (719,702) | (777,602) | |||
NOPBT Margin | ||||||
Operating Taxes | 67,420 | 32,776 | ||||
Tax Rate | ||||||
NOPAT | (443,148) | (787,122) | (810,378) | |||
Net income | (767,996) -9.23% | (846,135) 20.48% | (702,328) -57.79% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 27 | 94 | 697 | |||
BB yield | 0.00% | -0.01% | -0.01% | |||
| Debt | ||||||
Debt current | 121,005 | 152,900 | 20,186 | |||
Long-term debt | 254,085 | 136,828 | 142,035 | |||
Deferred revenue | ||||||
Other long-term liabilities | (92,500) | (95,000) | ||||
Net debt | (636,353) | (1,099,152) | (1,672,873) | |||
| Cash flow | ||||||
Cash from operating activities | (398,418) | (536,722) | (561,198) | |||
CAPEX | (12,409) | (76,874) | (73,087) | |||
Cash from investing activities | 9,904 | (124,083) | (137,130) | |||
Cash from financing activities | 275 | 112,354 | (30,621) | |||
FCF | (391,060) | (814,663) | (868,196) | |||
| Balance | ||||||
Cash | 1,011,443 | 1,388,880 | 1,835,094 | |||
Long term investments | ||||||
Excess cash | 1,002,750 | 1,381,595 | 1,833,554 | |||
Stockholders' equity | (4,965,307) | (3,726,476) | (3,289,809) | |||
Invested Capital | 6,967,940 | 6,355,860 | 6,222,233 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 411,530 | 410,093 | 399,749 | |||
Price | 2.26 -48.05% | 4.35 -66.28% | 12.90 -52.66% | |||
Market cap | 930,058 -47.86% | 1,783,905 -65.41% | 5,156,762 43.47% | |||
EV | 293,705 | 684,753 | 3,483,889 | |||
EBITDA | (343,314) | (638,336) | (731,275) | |||
EV/EBITDA | ||||||
Interest | 12,415 | 6,787 | 2,692 | |||
Interest/NOPBT | ||||||